Mark Alvino - Abeona Therapeutics Independent Director
| ABEO Stock | USD 7.53 0.40 5.04% |
Director
Mr. Mark J. Alvino is an Independent Director of Access Pharmaceuticals Inc. Mr. Alvino became a director in March 2006 initially as a designee of SCO Capital Partners LLC and is chairman of the Audit Committee. He is no longer a designee of SCO Capital Partners LLC. Mr. Alvino is also a member of the Compensation Committee and Nominating and Corporationrationrate Governance Committees. Mr. Alvino is currently with Hudson Square Capital LLC since October 2014. From 2013 to October 2014 Mr. Alvino was leading the LifeSciences efforts of Bradley Woods, Co. Ltd. Mr. Alvino was Managing Director for Griffin Securities from 2007 to 2013. Mr. Alvino was Managing Director for SCO Financial Group LLC from 2002 to 2007. Mr. Alvino was a member of the board of directors of MacroChem Corporation from 2007 until February 2009. He previously worked at Feinstein Kean Healthcare, an Ogilvy Public Relations Worldwide Company. There he was Senior Vice President, responsible for managing both investor and corporate communications programs for many private and public companies and acted as senior counsel throughout the agencys network of offices. Prior to working at FKH, Mr. Alvino served as Vice President of Investor Relations and managed the New York Office of Allen Caron, Inc., an investor relations agency. His base of clients included medical devices, biotechnology, and ehealthcare companies. Mr. Alvino also spent several years working with Wall Street brokerages including Ladenburg, Thallman Co. and Martin Simpson Co. Mr. Alvinos qualifications to serve our Board include his leadership skills and his experience in the areas of financial management and business strategy in the biopharmaceutical field. since 2006.
| Age | 49 |
| Tenure | 18 years |
| Address | 6555 Carnegie Avenue, Cleveland, OH, United States, 44103 |
| Phone | 646 813 4701 |
| Web | https://www.abeonatherapeutics.com |
Latest Insider Transactions
Alvino was a member of the board of directors of MacroChem Corporationration from 2007 until February 2009. He previously worked at Feinstein Kean Healthcare, an Ogilvy Public Relations Worldwide Company. There he was Senior Vice President, responsible for managing both investor and corporate communications programs for many private and public companies and acted as senior counsel throughout the agency’s network of offices. Prior to working at FKH, Mr. Alvino served as Vice President of Investor Relations and managed the New York Office of Allen & Caron, Inc., an investor relations agency.Abeona Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4699) % which means that it has lost $0.4699 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.606) %, meaning that it created substantial loss on money invested by shareholders. Abeona Therapeutics' management efficiency ratios could be used to measure how well Abeona Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -0.89. In addition to that, Return On Capital Employed is likely to grow to -0.91. At this time, Abeona Therapeutics' Other Current Assets are very stable compared to the past year. As of the 19th of April 2024, Non Currrent Assets Other is likely to grow to about 361.3 K, while Total Assets are likely to drop about 49.3 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Ann Barbier | Pieris Pharmaceuticals | N/A | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| Steven Prelack | Pieris Pharmaceuticals | 56 | |
| Barbara Duncan | Adaptimmune Therapeutics Plc | 53 | |
| Matthew Sherman | Pieris Pharmaceuticals | 61 | |
| Gary Bridger | X4 Pharmaceuticals | N/A | |
| Jerry Karabelas | Regenxbio | N/A | |
| David Mott | Adaptimmune Therapeutics Plc | 52 | |
| Jay Lobell | Fortress Biotech | 51 | |
| Deepa Pakianathan | Mereo BioPharma Group | 53 | |
| David Barrett | Fortress Biotech | 39 | |
| Alexandra Glucksmann | Regenxbio | 59 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| Michael Richman | Pieris Pharmaceuticals | 53 | |
| Andrew Saik | PDS Biotechnology Corp | 48 | |
| James Daly | ACADIA Pharmaceuticals | 56 | |
| Luke Beshar | Regenxbio | 59 | |
| Elliot Sigal | Adaptimmune Therapeutics Plc | 65 | |
| Michael Wyzga | Mereo BioPharma Group | 63 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.47 |
Abeona Therapeutics Leadership Team
Elected by the shareholders, the Abeona Therapeutics' board of directors comprises two types of representatives: Abeona Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abeona. The board's role is to monitor Abeona Therapeutics' management team and ensure that shareholders' interests are well served. Abeona Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abeona Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Carr, Vice President Controller | ||
| Mark Alvino, Independent Director | ||
| Kaye Spratt, Vice President - Regulatory & Quality Assurance | ||
| Carl Denny, Senior Affairs | ||
| Joseph CPA, Chief Officer | ||
| Madhav MBA, Chief VP | ||
| Joseph Vazzano, Chief Officer | ||
| Juan Ruiz, Chief Medical Officer | ||
| Andrea Lucca, Vice President - Communications & Operations | ||
| Christine BerniSilverstein, Vice President Investor Relations | ||
| Stefano Buono, Director | ||
| Brian Kevany, CTO VP | ||
| Alison Hardgrove, Vice Resources | ||
| Richard Duyne, Director | ||
| Todd Wider, Director | ||
| Jon Voss, VP Quality | ||
| Frank Thiel, CEO | ||
| Dr JD, Senior Counsel | ||
| Max Colao, Chief Commercial Officer | ||
| Timothy Miller, CEO and President and Director | ||
| Mark Ahn, Independent Director | ||
| Steven Rouhandeh, Executive Chairman of the Board | ||
| Stephen Howell, Independent Director | ||
| Joao Siffert, Executive Vice President Chief Medical Officer, Head of Research and Development | ||
| David Nowotnik, Senior Vice President - Research and Development | ||
| Jeffrey Davis, COO and Director | ||
| Neena Patil, General Counsel and Corporate Secretary | ||
| Dmitriy MD, Chief Officer | ||
| Phil Maples, Vice President - Therapeutics Development and Quality Management | ||
| Harrison Wehner, CFO | ||
| Vishwas MBA, CEO President | ||
| Scott Santiamo, Director Communications | ||
| Stephen Thompson, Chief Accounting Officer, VP of Fin., Treasurer and Secretary | ||
| Christine Berni, Director - Investor Relations | ||
| Gregory Gin, Vice Communications | ||
| Michelle Berg, Vice President - Communications & Operations |
Abeona Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abeona Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (13.77) % | ||||
| Current Valuation | 170.1 M | ||||
| Shares Outstanding | 27.36 M | ||||
| Shares Owned By Insiders | 4.94 % | ||||
| Shares Owned By Institutions | 59.93 % | ||||
| Number Of Shares Shorted | 1.99 M | ||||
| Price To Earning | 0.11 X | ||||
| Price To Book | 13.93 X |
Pair Trading with Abeona Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Abeona Stock
| 0.55 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.Note that the Abeona Therapeutics information on this page should be used as a complementary analysis to other Abeona Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Abeona Stock analysis
When running Abeona Therapeutics' price analysis, check to measure Abeona Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abeona Therapeutics is operating at the current time. Most of Abeona Therapeutics' value examination focuses on studying past and present price action to predict the probability of Abeona Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abeona Therapeutics' price. Additionally, you may evaluate how the addition of Abeona Therapeutics to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Abeona Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.53) | Revenue Per Share 0.164 | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (2.61) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.